Sunil Solomon, MBBS, PhD, MPH

CRS:

JHU

Role:

Investigators

Position:

Investigator

Sunil Suhas Solomon, MBBS PhD MPH is a Professor of Medicine, in the Division of Infectious Diseases, at the Johns Hopkins University School of Medicine. He is also the Chairman of the YR Gaitonde Medical Educational and Research Foundation, Chennai, India. He completed his medical training at the Sri Ramachandra Medical University in Chennai, India and received a Masters in Public Health and a doctorate in Epidemiology (PhD) from the Johns Hopkins University, USA. Dr. Solomon has been elected into the Phi Beta Kappa honors society for academic excellence and the Delta Omega Public Health honors society. His research is focused on the epidemiology, clinical management and access to HIV and HCV care among vulnerable Indian populations such as people who inject drugs and men who have sex with men. He has over 100 peer-reviewed publication in several highly ranked journals such as the Lancet ID, PLOS Medicine, Lancet HIV, Clinical Infectious Diseases, American Journal of Epidemiology, Addiction and AIDS. In 2015, he was one of the first recipients of the Avenir award, a Director’s award from the National Institutes of Health, USA aimed at identifying individuals who propose high impact research and who show promise of being tomorrow's leaders in the field of drug abuse and HIV.

  • Investigator, Hepatitis TSG (Dec 2015-present)
  • Investigator, A5380
  • Chair, A5360

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More

A5302:  BioBank for Surrogate Marker Research for TB...

Primary Objective To obtain sputum, serum, urine, and peripheral blood mononuclear cells (PBMCs) for central TB biorepository...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More